Comparative efficacy of total en-bloc spondylectomy and separation surgery followed by stereotactic body radiotherapy for isolated spinal metastases in lung cancer patients: a retrospective study Authors: Zhipeng Zhu, Hao Yuan, Zhilong Shen, Hongyu Liu, Bo Li, Wei Xu Published: 2026 ABSTRACT ObjectiveTo compare the clinical efficacy between total en bloc spondylectomy (TES) and separation surgery combined with stereotactic body radiotherapy (SSRS) in patients with isolated spinal metastases secondary to NSCLC.MethodsA total of 85 NSCLC patients diagnosed with isolated spinal metastases were enrolled in this retrospective analysis. All patients received treatment between June 2018 and April 2022, among whom 25 patients underwent TES and the remaining 60 patients were managed with SSRS. Evaluated endpoints included local tumor control, PFS, OS, postoperative complications, and quality of life assessed via the SOSGOQ scale.ResultsTES yielded superior local tumor control and significantly prolonged PFS relative to SSRS. Nevertheless, the TES group presented larger intraoperative blood loss and a higher postoperative complication incidence. Specifically, cerebrospinal fluid leakage occurred in 20% of TES patients and pleural rupture in 12%, whereas both complications only accounted for 3.3% in the SSRS cohort. No significant intergroup difference was observed in OS.ConclusionTES provides superior local tumor control and extended PFS for NSCLC patients with isolated spinal metastases, accompanied by increased intraoperative blood loss and higher complication risks. OS remains comparable between the two therapeutic modalities. Both approaches effectively improve patients’ postoperative quality of life. These outcomes highlight the necessity of multidisciplinary collaborative decision-making to individualize and optimize therapeutic strategies for this clinical population. Introduction NSCLC remains one of the leading causes of cancer-related death worldwide [1]. Approximately 30–40% of patients with advanced NSCLC develop bone metastases, with the spine being the most common site [2]. Spinal metastases frequently cause serious complications, including spinal cord compression and pathological fractures, which markedly impair patients’ quality of life and escalate healthcare costs [3, 4]. Although bone metastases in NSCLC have historically been associated with a median survival of approximately one year, outcomes are now more heterogeneous in the modern treatment era, with some patients achieving substantially longer survival, particularly in the presence of actionable mutations [5–8]. Oligometastatic disease is recognized as a unique metastatic subtype of NSCLC, which is characterized by restricted metastatic dissemination and indolent disease progression [9]. Patients diagnosed with isolated spinal metastases stand to gain substantial survival benefits from definitive local therapeutic interventions, as such strategies markedly enhance both PFS and OS [10–13]. Therapeutic regimens for spinal metastatic lesions have advanced substantially in recent decades, and stereotactic body radiotherapy (SBRT) has emerged as a mainstream treatment modality by virtue of its outstanding targeting accuracy and favorable efficacy in local tumor control [14]. Even so, surgical intervention still serves as an indispensable pillar of multidisciplinary comprehensive management, especially for patients with solitary spinal metastases [15]. Total en bloc spondylectomy (TES) [16] and separation surgery combined with subsequent SBRT (SSRS) [17] constitute the two predominant surgical paradigms currently applied for this clinical scenario. While the National Comprehensive Cancer Network (NCCN) has established well-defined therapeutic guidelines for NSCLC patients with brain and adrenal metastases, dedicated consensus recommendations for bone metastasis management—particularly for isolated spinal lesions—remain insufficient [18]. This clinical guideline vacuum results in substantial heterogeneity in real-world clinical practice, and no unified consensus has yet been reached on the optimal surgical strategy for this patient cohort. Accordingly, the present study aims to retrospectively compare the clinical outcomes of TES and SSRS in NSCLC patients with isolated spinal metastases, with a focus on key endpoints including local tumor control, postoperative complications, survival, and quality of life as assessed by the SOSGOQ. The ultimate objective is to furnish evidence-based recommendations that can optimize clinical decision-making for the management of this patient population. Methods Study design and patient selection This retrospective cohort study was performed at Changzheng Hospital, based on patient medical records from June 2018 to April 2022. A total of 124 NSCLC patients with spinal metastases were initially screened (Fig. 1). Following the application of predefined inclusion and exclusion criteria, 85 patients were ultimately enrolled in the final analysis. Among them, 25 underwent TES, and 60 received separation surgery followed by SSRS. Fig. 1Patient selection flow diagram Patient selection flow diagram The inclusion criteria were as follows: (1) Primary tumor site confirmed as NSCLC. (2) Solitary spinal metastasis was defined as a single metastatic lesion confined to one vertebral level (vertebral body and/or posterior elements), with no evidence of additional spinal or extra-spinal bone metastases on whole-spine MRI, CT and ¹⁸F-FDG PET-CT at the time of diagnosis. Surgical indications were determined according to the NOMS framework, including: ① Spinal instability (SINS ≥ 7, with SINS ≥ 13 indicating definite instability) ; ② High-grade epidural spinal cord compression (Bilsky grade 2–3) ; ③Progressive neurological deficit; ④ impending or pathological vertebral fracture; and ⑤ Intractable mechanical pain refractory to conservative management. (3) The treatment strategy (TES vs. SSRS) was determined through multidisciplinary team discussion, with TES prioritized for patients with limited mechanical instability and favorable systemic disease, and SSRS for those with high-grade epidural compression or elevated surgical risk. (4) Life expectancy of more than six months (Fig. 2). Fig. 2Key steps in total en-bloc spondylectomy (TES) Key steps in total en-bloc spondylectomy (TES) Exclusion criteria were as follows: (1) Multiple spinal metastases or other metastatic disease. (2) Preoperative radiotherapy or history of spinal surgery. (3) Patients with total paraplegia or neurological deficits lasting more than 48 h. (4) Tumor compressing only the cauda equina or spinal roots. (5) Patients lost to follow-up. Data collection The baseline data collected included patient demographics (age, sex, BMI, smoking history), site of spinal metastasis, pathological type of NSCLC, and any detected genetic mutations. Clinical data also included preoperative scores like the revised Tokuhashi score, Spinal Instability Neoplastic Score (SINS), Karnofsky Performance Status (KPS), and the Eastern Cooperative Oncology Group (ECOG) performance status. Information on the use of bone-modifying agents (BMAs), targeted therapies, and prior lung surgeries were also recorded. Laboratory data such as white blood cell (WBC) counts and C-reactive protein (CRP) levels were documented. Surgical approach The study compared two surgical approaches: TES involves the complete removal of the affected vertebra and surrounding tumor tissue in one piece to achieve wide oncological margins. After removal, the spine is reconstructed using artificial vertebrae, titanium cages, and bone grafts. SSRS involves separation surgery, where the tumor is dissected away from the dura mater without complete vertebra removal. After surgery, stereotactic body radiotherapy (SBRT) is applied within 20–30 days using high-dose hypofractionated radiotherapy. Both surgical procedures involved the use of preoperative MRI and CT scans to map the tumor and surrounding structures. Intraoperative neuromonitoring was employed to ensure spinal cord function during the procedures. Pedicle screws and rods were used to stabilize the spine during and after surgery. Follow-up and outcome measures Patients were followed up at 3-, 6-, 9-, and 12-months post-surgery and then every 4 months for 2 years, and once a year thereafter. Clinical outcomes assessed included: (1) Overall survival (OS) and PFS. (2) Postoperative complications, such as intraoperative blood loss and cerebrospinal fluid (CSF) leakage. (3) Neurological function recovery and pain relief were assessed using established scoring systems. (4) Quality of life scores measured with SOSGOQ. Statistical analysis Continuous variables were presented as mean ± standard deviation (SD) and analyzed using the Mann-Whitney U test. Categorical data were compared using Fisher’s exact test. Survival outcomes were assessed using Kaplan-Meier curves and the log-rank test for group comparisons. Cox proportional hazards regression was used for multivariate analysis, with results expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). A p-value < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS (version 25.0) and R (version 4.1.2). Results Baseline demographic characteristics showed no significant differences between the two groups (p > 0.05). As shown in Table 1, metastatic sites in the TES group were distributed as thoracic (24%), lumbar (20%), cervical (36%), and sacral (20%). In the SSRS group, metastatic lesions located in the thoracic (33.3%), lumbar (35%), cervical (21.7%), and sacral (10%) regions. Adenocarcinoma was the dominant pathological type, which accounted for 64% of TES cases and 81.7% of SSRS cases. In terms of genetic alterations, EGFR mutations occurred in 20% of TES patients and 30% of SSRS patients, while ALK rearrangements presented in 8% and 10% of the two groups respectively. Postoperative bone-modifying agents (BMAs) were applied to 44% of TES patients and 47% of SSRS patients. Postoperative adjuvant therapies, including chemotherapy, radiotherapy and targeted therapy, were administered to 52% of TES patients and 55% of SSRS patients. Table 1Baseline characteristics of the enrolled patientsFactorsTES (N = 25)SSRS (N = 60)p-valueSex(Male,%)13 (52%)34 (56.7%)0.877Age< 6010 (40%)24 (40%)0.873≥ 6015 (60%)36 (60%)BMI< 194 (16%)7 (11.7%)0.79719–2410 (40%)28 (46.7%)> 2411 (44%)25 (41.7%)SmokingNO19 (76%)44 (73.3%)0.939<=201 (4%)2 (3.3%)0.939> 205 (20%)14 (23.3%)Sitecervical9 (36%)13 (21.7%)0.207thoracic6 (24%)20 (33.3%)lumbar5 (20%)21 (35%)sacrum5 (20%)6 (10%)Pathological typesquamous1 (4%)3 (5%)0.134adenocarcinoma16 (64%)49 (81.7%)other8 (32%)8 (13.3%)Gene•EGFR mutation0.169Yes6 (24%)24 (40%)No10(40%)18(30%)KRAS mutationYes2 (8%)1 (1.7%)No7(28%)17(28.3)Strength00 (0%)4 (6.7%)0.25910 (0%)1 (1.7%)22 (8%)8 (13.3%)36 (24%)11 (18.3%)49 (36%)28 (46.7%)58 (32%)8 (13.3%)The revised Tokuhashi8.0 ± 1.37.9 ± 1.30.801SINS10.4 ± 1.89.2 ± 1.20.006KPS67.6 ± 15.474.2 ± 15.00.071ECOG04 (16.7%)14 (23.7%)0.84414 (16.7%)11 (18.6%)26 (25%)14 (23.7%)33 (12.5%)9 (15.3%)47 (29.2%)11 (18.6%)Bone modifying agents (Y, %)10 (40%)23 (38.3%)1Targeted drug (Y, %)11 (44%)28 (46.7%)1Target time (month)10.4 ± 15.010.2 ± 13.40.974Lung Radiotherapy (Y, %)7 (28%)13 (21.7%)0.729Lung surgery (Y, %)1 (4%)2 (3.3%)1The TES group had a significantly higher mean SINS score compared to the SSRS group (10.4 ± 1.8 vs. 9.2 ± 1.2, p = 0.006), indicating more severe spinal instability in the TES cohort. This difference reflects the treatment selection process, as TES was preferentially performed in patients with more advanced local disease. We addressed this imbalance by including SINS as a covariate in the univariate Cox analysis; however, it was not included in the multivariable model due to collinearity with surgery type and the risk of overfitting Table 1Baseline characteristics of the enrolled patientsFactorsTES (N = 25)SSRS (N = 60)p-valueSex(Male,%)13 (52%)34 (56.7%)0.877Age< 6010 (40%)24 (40%)0.873≥ 6015 (60%)36 (60%)BMI< 194 (16%)7 (11.7%)0.79719–2410 (40%)28 (46.7%)> 2411 (44%)25 (41.7%)SmokingNO19 (76%)44 (73.3%)0.939<=201 (4%)2 (3.3%)0.939> 205 (20%)14 (23.3%)Sitecervical9 (36%)13 (21.7%)0.207thoracic6 (24%)20 (33.3%)lumbar5 (20%)21 (35%)sacrum5 (20%)6 (10%)Pathological typesquamous1 (4%)3 (5%)0.134adenocarcinoma16 (64%)49 (81.7%)other8 (32%)8 (13.3%)Gene•EGFR mutation0.169Yes6 (24%)24 (40%)No10(40%)18(30%)KRAS mutationYes2 (8%)1 (1.7%)No7(28%)17(28.3)Strength00 (0%)4 (6.7%)0.25910 (0%)1 (1.7%)22 (8%)8 (13.3%)36 (24%)11 (18.3%)49 (36%)28 (46.7%)58 (32%)8 (13.3%)The revised Tokuhashi8.0 ± 1.37.9 ± 1.30.801SINS10.4 ± 1.89.2 ± 1.20.006KPS67.6 ± 15.474.2 ± 15.00.071ECOG04 (16.7%)14 (23.7%)0.84414 (16.7%)11 (18.6%)26 (25%)14 (23.7%)33 (12.5%)9 (15.3%)47 (29.2%)11 (18.6%)Bone modifying agents (Y, %)10 (40%)23 (38.3%)1Targeted drug (Y, %)11 (44%)28 (46.7%)1Target time (month)10.4 ± 15.010.2 ± 13.40.974Lung Radiotherapy (Y, %)7 (28%)13 (21.7%)0.729Lung surgery (Y, %)1 (4%)2 (3.3%)1The TES group had a significantly higher mean SINS score compared to the SSRS group (10.4 ± 1.8 vs. 9.2 ± 1.2, p = 0.006), indicating more severe spinal instability in the TES cohort. This difference reflects the treatment selection process, as TES was preferentially performed in patients with more advanced local disease. We addressed this imbalance by including SINS as a covariate in the univariate Cox analysis; however, it was not included in the multivariable model due to collinearity with surgery type and the risk of overfitting Baseline characteristics of the enrolled patients • EGFR mutation The TES group had a significantly higher mean SINS score compared to the SSRS group (10.4 ± 1.8 vs. 9.2 ± 1.2, p = 0.006), indicating more severe spinal instability in the TES cohort. This difference reflects the treatment selection process, as TES was preferentially performed in patients with more advanced local disease. We addressed this imbalance by including SINS as a covariate in the univariate Cox analysis; however, it was not included in the multivariable model due to collinearity with surgery type and the risk of overfitting As presented in Table 2, surgical outcome analysis indicated that overall survival (OS) differed slightly between the TES and SSRS groups (p = 0.330). Intraoperative blood loss was higher in the TES group, with a mean value of 1128.0 ± 601.1 ml, compared with 810.3 ± 344.1 ml in the SSRS group (p = 0.019). Table 2Comparison of major results after surgery in the two groupsFactorsTES(N = 25)SSRS (N = 60)p-valueOS(95%CI)350(270.9,429.1)410(330.9-489.1)0.330PFS(95%CI)304(50.2, 457.8)210(144.9,275.1)0.044Bleeding1128.0 ± 601.1810.3 ± 344.10.019complicationNO15 (60%)49 (81.7%)0.024Cerebrospinal fluid leakage5 (20%)2 (3.3%)pleural rupture3 (12%)2 (3.3%)Pneumonia2 (8%)3 (5%)Wound infection0 (0%)4 (6.7%) The TES group had a higher incidence of postoperative complications. Complications occurred in 10 patients (40.0%) in the TES group and 11 patients (18.3%) in the SSRS group (p = 0.024).Cerebrospinal fluid leakage occurred in 5 patients (20%) in the TES group and 2 patients (3.3%) in the SSRS group. Pleural rupture was more common in the TES group, affecting 3 patients (12%) versus 2 patients (3.3%) in the SSRS group. Wound infections happened in 0 patients of the TES group and 4 patients (6.7%) of the SSRS group, with a comparable risk between cohorts. These findings suggested that TES achieved better tumor control but carried a higher risk of postoperative complications, especially cerebrospinal fluid leakage and pleural rupture. Table 2Comparison of major results after surgery in the two groupsFactorsTES(N = 25)SSRS (N = 60)p-valueOS(95%CI)350(270.9,429.1)410(330.9-489.1)0.330PFS(95%CI)304(50.2, 457.8)210(144.9,275.1)0.044Bleeding1128.0 ± 601.1810.3 ± 344.10.019complicationNO15 (60%)49 (81.7%)0.024Cerebrospinal fluid leakage5 (20%)2 (3.3%)pleural rupture3 (12%)2 (3.3%)Pneumonia2 (8%)3 (5%)Wound infection0 (0%)4 (6.7%) Comparison of major results after surgery in the two groups Table 3 compared preoperative and postoperative quality of life (QoL) scores between the two groups in terms of mental health, social function, pain and physical function. In the TES group, mental health scores improved from 45.0 preoperatively to 65.0 postoperatively, and the scores rose from 46.0 to 64.0 in the SSRS group. Pain scores increased from 34.0 to 52.0 in TES patients and from 33.0 to 51.0 in SSRS patients, which reflected effective postoperative pain relief. Physical function scores also improved obviously, rising from 47.0 to 60.0 in the TES group and from 46.5 to 59.0 in the SSRS group. Both groups showed significant postoperative improvements in all QoL domains compared with baseline, while no significant intergroup differences existed in any postoperative QoL dimension (Tables 4 and 5). Table 3Quality of life scores measured with SOSGOQDomainPre-Surgery -TES (n = 25)Pre-Surgery -SSRS (n = 60)Pre-Surgery P-value6 Months Post-Surgery -TES(n = 25)6 Months Post-Surgery -SSRS(n = 60)Post-Surgery P-valueMental Health45.0 ± 16.546.0 ± 15.00.82065.0 ± 14.064.0 ± 14.50.760Social Function41.0 ± 13.042.0 ± 12.50.75043.5 ± 10.042.5 ± 11.00.700Pain34.0 ± 15.533.0 ± 14.00.79052.0 ± 13.051.0 ± 13.50.680Physical Function47.0 ± 16.046.5 ± 15.00.88060.0 ± 11.559.0 ± 11.00.570Total Score42.0 ± 14.043.5 ± 13.50.76055.0 ± 12.554.0 ± 12.00.700 Table 3Quality of life scores measured with SOSGOQDomainPre-Surgery -TES (n = 25)Pre-Surgery -SSRS (n = 60)Pre-Surgery P-value6 Months Post-Surgery -TES(n = 25)6 Months Post-Surgery -SSRS(n = 60)Post-Surgery P-valueMental Health45.0 ± 16.546.0 ± 15.00.82065.0 ± 14.064.0 ± 14.50.760Social Function41.0 ± 13.042.0 ± 12.50.75043.5 ± 10.042.5 ± 11.00.700Pain34.0 ± 15.533.0 ± 14.00.79052.0 ± 13.051.0 ± 13.50.680Physical Function47.0 ± 16.046.5 ± 15.00.88060.0 ± 11.559.0 ± 11.00.570Total Score42.0 ± 14.043.5 ± 13.50.76055.0 ± 12.554.0 ± 12.00.700 Quality of life scores measured with SOSGOQ Table 4Univariate Cox regression analysis resultsVariableUnivariate p.valueUnivariate HR (95% CI for HR)Age0.0281 (1-1.1)Sex0.0170.53 (0.31–0.89)Smoking0.241.2 (0.89–1.6)Strength0.160.87 (0.71–1.1)ECOG0.0351.2 (1-1.5)Tokuhashi0.621.1 (0.86–1.3)SINS0.771 (0.87–1.2)KPS0.751 (0.98-1)Pathological type0.40.76 (0.4–1.5)Site0.240.85 (0.65–1.1)Bone modifying agents0.000110.3 (0.17–0.56)Targeted drug0.00110.41 (0.24–0.7)Lung Radiotherapy0.0110.42 (0.21–0.82)Lung surgery0.520.52 (0.072-3.8)Complication0.580.94 (0.75–1.2)Surgery type0.330.76 (0.44–1.3)Bleeding volume0.721 (1–1) Table 4Univariate Cox regression analysis resultsVariableUnivariate p.valueUnivariate HR (95% CI for HR)Age0.0281 (1-1.1)Sex0.0170.53 (0.31–0.89)Smoking0.241.2 (0.89–1.6)Strength0.160.87 (0.71–1.1)ECOG0.0351.2 (1-1.5)Tokuhashi0.621.1 (0.86–1.3)SINS0.771 (0.87–1.2)KPS0.751 (0.98-1)Pathological type0.40.76 (0.4–1.5)Site0.240.85 (0.65–1.1)Bone modifying agents0.000110.3 (0.17–0.56)Targeted drug0.00110.41 (0.24–0.7)Lung Radiotherapy0.0110.42 (0.21–0.82)Lung surgery0.520.52 (0.072-3.8)Complication0.580.94 (0.75–1.2)Surgery type0.330.76 (0.44–1.3)Bleeding volume0.721 (1–1) Univariate Cox regression analysis results Table 5Multivariate Cox regression analysis resultsVariableβSEWaldX2Multivariatep.valueMultivariate HR (95% CI for HR)Age < 60Reference ≥ 600.3510.1853.600.0581.42(0.988–2.041)Sex FemaleReference Male0.3260.1316.1930.0131.385(1.072–1.791)ECOG 0–2Reference 3–40.2650.1046.4930.0111.303(1.063–1.598)Targeted drug YesReference No0.2440.1035.6120.0181.276(1.043–1.562)Lung Radiotherapy YesReference No0.3620.1585.2491.436(1.054–1.958) Table 5Multivariate Cox regression analysis resultsVariableβSEWaldX2Multivariatep.valueMultivariate HR (95% CI for HR)Age < 60Reference ≥ 600.3510.1853.600.0581.42(0.988–2.041)Sex FemaleReference Male0.3260.1316.1930.0131.385(1.072–1.791)ECOG 0–2Reference 3–40.2650.1046.4930.0111.303(1.063–1.598)Targeted drug YesReference No0.2440.1035.6120.0181.276(1.043–1.562)Lung Radiotherapy YesReference No0.3620.1585.2491.436(1.054–1.958) Multivariate Cox regression analysis results As shown in Fig. 3, Kaplan–Meier survival analysis revealed no significant difference in overall survival between the TES and SSRS groups (p = 0.330), which indicated that surgical selection of TES or SSRS exerted no significant influence on overall survival of patients with isolated spinal metastases. In contrast, Fig. 4 showed that the TES group obtained significantly longer progression-free survival (PFS) than the SSRS group (p = 0.044), which demonstrated that TES provided superior local tumor control and delayed disease progression more effectively than SSRS. As shown in Tables 4 and 5, univariate Cox regression analysis identified age, sex, ECOG performance status, bone-modifying agent use, targeted therapy, and lung radiotherapy as factors associated with postoperative OS. Considering the limited sample size and the potential risk of model overfitting, a parsimonious multivariate Cox regression model was constructed using clinically relevant variables. In the multivariate Cox regression model, age ≥60 years, male sex, ECOG performance status 3–4, absence of targeted therapy, and absence of lung radiotherapy were associated with poorer OS in patients with spinal metastases from NSCLC. Fig. 3OS after TES versus SSRS in patients with isolated spinal metastasis from NSCLC. Kaplan–Meier curves depict OS over follow-up time (days) (log-rank test, p = 0.33) OS after TES versus SSRS in patients with isolated spinal metastasis from NSCLC. Kaplan–Meier curves depict OS over follow-up time (days) (log-rank test, p = 0.33) Fig. 4PFS after TES versus SSRS in patients with isolated spinal metastasis from NSCLC. Kaplan–Meier curves depict PFS over follow-up time (days) (log-rank test, p = 0.044) PFS after TES versus SSRS in patients with isolated spinal metastasis from NSCLC. Kaplan–Meier curves depict PFS over follow-up time (days) (log-rank test, p = 0.044) Discussion This study retrospectively compared the outcomes of TES and SSRS in patients with isolated spinal metastases from NSCLC. Key outcomes analyzed included PFS, OS, postoperative complications, and QoL. The results showed that TES provided longer PFS than SSRS, but there was no significant difference in OS between the two groups. TES was associated with a higher rate of postoperative complications, particularly cerebrospinal fluid leakage and pleural rupture. In terms of QoL, both groups showed improvements postoperatively, with no significant difference between TES and SSRS. Multivariate Cox regression analysis suggested that age ≥60 years, male sex, ECOG performance status 3–4, absence of targeted therapy, and absence of lung radiotherapy were associated with poorer OS in patients with spinal metastases from NSCLC. Our study found that TES was associated with significantly higher intraoperative blood loss than SSRS (1128.0 ± 601.1 mL vs. 810.3 ± 344.1 mL, p = 0.019), consistent with prior studies showing greater blood loss with TES [19–22] and lower blood loss with SSRS [15, 23, 24]. These findings confirm the advantage of SSRS in reducing intraoperative blood loss. TES was associated with higher complication rates in our study, consistent with prior reports [19, 21, 25, 26], while SSRS had significantly lower rates [23], confirming its safety advantage. Thus, SSRS is preferred for high-risk patients, and surgical selection should be individualized. TES achieved better local control (8% vs. 15% recurrence) and longer PFS (p = 0.044) than SSRS, consistent with prior studies [16, 23, 25, 27]. These results confirm the advantage of TES in delaying disease progression. OS was similar between TES and SSRS in our study (p = 0.330), consistent with previous reports [16, 23, 27]. TES achieved better local control through en-bloc resection, which delays disease progression and potentially improves quality of life, making it a valuable option for prolonging PFS. The discrepancy between improved PFS and comparable OS can be explained by several factors. Firstly, the survival of NSCLC patients with spinal metastases is predominantly determined by systemic disease progression and the effectiveness of systemic, rather than local control alone. Second, patients in the SSRS group who experienced local recurrence could receive salvage treatments, including repeat surgery or re-irradiation, which may have attenuated the survival disadvantage associated with inferior local control. Third, the follow-up period may have been insufficient to detect OS differences, particularly given the heterogeneous survival outcomes in the modern treatment era. Therefore, while both approaches may be acceptable from an OS perspective, TES offers superior local control and longer PFS, which may translate into better quality of life and delayed need for further interventions. The choice between TES and SSRS should be individualized based on patient fitness, tumor characteristics, and treatment goals. The univariate and multivariate analyses in this study identified several key factors influencing the OS of patients with isolated spinal metastasis from NSCLC. Systemic therapies, including denosumab [28, 29], EGFR-targeted agents [30, 31], and radiotherapy [32, 33], significantly improve survival. Therefore, a multidisciplinary strategy combining surgery with these modalities is essential for optimal outcomes in NSCLC patients with isolated spinal metastases. Although the present study identified significant survival benefits associated with targeted therapy and bone-modifying agents (BMAs), the potential interaction between systemic treatment and the choice of surgical approach (TES vs. SSRS) was not further explored due to the limited sample size and the retrospective nature of the data. Given the established role of systemic therapy in non-small cell lung cancer (NSCLC), understanding whether the relative efficacy of TES and SSRS differs according to the use of targeted agents or BMAs would be of great clinical interest. However, such subgroup or interaction analyses were beyond the scope of this study and could be better addressed in future prospective, adequately powered cohorts. Nonetheless, our findings underscore that optimal outcomes in patients with isolated spinal metastases likely depend on a combination of local surgical control and effective systemic therapy, rather than the surgical modality alone. This study has several limitations. Firstly, its retrospective design introduces the possibility of selection bias and uncontrolled confounding variables. The imbalance in EGFR mutation status between groups (24% in TES vs. 40% in SSRS) represents a potential source of confounding by tumor biology. Secondly, the multivariable Cox analysis was subject to overfitting due to the relatively large number of variables included relative to the sample size. In the revised analysis, we adopted a more parsimonious model; however, the small sample size still limits the precision of effect estimates. Third, potential collinearity and overadjustment—particularly between gene status and targeted therapy, as well as among performance status measures (ECOG, KPS, and muscle strength)—should be acknowledged. Fourth, the inclusion of treatment-related variables (e.g., lung radiotherapy, targeted therapy) in the original multivariable model may have complicated causal interpretation, as these variables reflect treatment selection and underlying tumor biology rather than independent baseline prognostic factors. Finally, the absence of a non-surgical control group limits our ability to compare surgical interventions against conservative management. Future prospective studies with larger cohorts and standardized treatment protocols are needed to validate our findings. Additionally, the significant difference in baseline SINS scores between groups suggests differential disease severity, which may confound the comparison of surgical outcomes. What is more, the clinically relevant imbalance in EGFR mutation status between groups represents a potential source of confounding by tumor biology. Although our stratified analysis showed consistent effects across subgroups and the multivariable model adjusted for targeted therapy, residual confounding by unmeasured tumor characteristics cannot be entirely excluded. Conclusion This study compares TES and SSRS for treating isolated spinal metastases in NSCLC patients. TES offers better local tumor control and longer progression-free survival but is more invasive, leading to higher blood loss and complication rates. SSRS is less invasive with fewer complications, making it preferable for high-risk patients. Although TES is more effective at delaying disease progression, it does not significantly improve overall survival, indicating that systemic therapies play a critical role in improving overall prognosis. Clinical decisions should be personalized, considering patient health and tumor characteristics to optimize treatment outcomes.